{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:29:07Z","timestamp":1792621747249,"version":"4.5.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Chemotherapeutic agents can have both serious side effects and ototoxicity, which can be caused by direct toxic effects or by metabolic derangement by the agents. Cabazitaxel (CBZ) is a next-generation semi-synthetic taxane derivative that is effective in both preclinical models of human tumors that are sensitive or resistant to chemotherapy and in patients suffering from progressive prostate cancer despite docetaxel treatment. The primary aim of this study is to investigate the ototoxicity of CBZ in a rat model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A total of 24 adult male Wistar-Albino rats were equally and randomly divided into four groups. CBZ (Jevtana, Sanofi-Aventis USA) was intraperitoneally administered to Groups 2, 3, and 4 at doses of 0.5, 1.0, and 1.5 mg\/kg\/week, respectively, for 4 consecutive weeks; Group 1 received only i.p. saline at the same time. At the end of the study, the animals were sacrificed and their cochlea removed for histopathological examination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Intraperitoneal administration of CBZ exerted an ototoxic effect on rats, and the histopathological results became worse in a dose-dependent manner (P &lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings suggest that CBZ may be an ototoxic agent and can damage the cochlea. More clinical studies should be conducted to understand its ototoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_774_21","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:25:21Z","timestamp":1681896321000},"page":"S314-S317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Cabazitaxel\u2019s ototoxicity: An animal study and histopathologic research"],"prefix":"10.4103","volume":"19","author":[{"given":"Abdulkadir","family":"Bucak","sequence":"first","affiliation":[{"name":"Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Pathology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"K\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eahin","family":"Ulu","sequence":"additional","affiliation":[{"name":"Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sel\u00e7uk","family":"Kuzu","sequence":"additional","affiliation":[{"name":"Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011flar","family":"G\u00fcnebakan","sequence":"additional","affiliation":[{"name":"Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan Kemal","family":"Kahveci","sequence":"additional","affiliation":[{"name":"Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"R2-20241021","first-page":"440","article-title":"Cabazitaxel (jevtana): A novel agent for metastatic castration-resistant prostate cancer","volume":"37","author":"Nightingale","year":"2012","journal-title":"P T"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2012.07.008","article-title":"Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study","volume":"49","author":"Di\u00e9ras","year":"2013","journal-title":"Eur J Cancer"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer"},{"key":"R5-20241021","first-page":"239","article-title":"Paraclinical evaluation of side-effects of Taxanes on auditory system","volume":"28","author":"Sarafraz","year":"2008","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/lary.25031","article-title":"Investigation of protective role of curcumin against paclitaxel-induced inner ear damage in rats","volume":"125","author":"Bucak","year":"2015","journal-title":"Laryngoscope"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1634\/theoncologist.2010-0412","article-title":"Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting","volume":"16","author":"Sartor","year":"2011","journal-title":"Oncologist"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ijporl.2005.11.011","article-title":"Investigation of ototoxic effects of Taxol on a mice model","volume":"70","author":"Atas","year":"2006","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.taap.2014.08.022","article-title":"Ototoxicity of paclitaxel in rat cochlear organotypic cultures","volume":"280","author":"Dong","year":"2014","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_774_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:37Z","timestamp":1787067577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_774_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":10,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_774_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"2021-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}